Regenxbio price target lowered to $32 from $34 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $32 from $34 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA for RGX-121 for the treatment of mucopolysaccharidosis II. This is in line with expectations following the clinical hold last month, the analyst tells investors in a research note.